COMP <GO>
IRWD vs UNH // EV/EBITDA & P/E VALUATION
Ironwood Pharmaceuticals Inc. (Class A) (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: IRWD 5
— UNH 6
▲ EV/EBITDA & P/E VALUATION LEADER: IRWD
LAST: $3.62 (+0.28%) • MKT CAP: $598.2M
valuation
3.9x
LAST: $410.91 (+0.94%) • MKT CAP: $368.83B
valuation
16.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IRWD VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IRWD | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 88.57% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | 11.47% | +73.53 | IRWD | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 3.9x | 16.4x | -12.55 | IRWD | /valuation <GO> |
| Free Cash Flow Yield | 21.23% | 6.48% | +14.75 | IRWD | /fcf-yield <GO> |
| Operating Margin | 33.30% | 4.82% | +28.48 | IRWD | /operating-margins <GO> |
| Net Profit Margin | 8.10% | 3.14% | +4.96 | IRWD | /net-margins <GO> |
| Revenue Growth (YoY) | -15.70% | 6.46% | -22.16 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 3.12 | -2.92 | UNH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.5 | 59.2 | -18.69 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 23.2x | 17.1x | +6.11 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $598.2M | $368.83B | -$368.23B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IRWD REV | UNH REV | IRWD GROSS % | UNH GROSS % | IRWD FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $296.2M | $447.57B | — | 88.7% | $127.0M | $16.07B |
| FY 2024 | $351.4M | $400.28B | — | 88.3% | $103.4M | $20.70B |
| FY 2023 | $442.7M | $371.62B | — | 89.6% | $183.4M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IRWD // BETA —
UNH // BETA 0.33